Patents Assigned to Bionomics Limited
  • Patent number: 10266529
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 23, 2019
    Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Patent number: 10233181
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Patent number: 10213409
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: February 26, 2019
    Assignee: BIONOMICS LIMITED
    Inventors: Jason Hugh Chaplin, Gurmit Sing Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Patent number: 10159659
    Abstract: The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: December 25, 2018
    Assignee: BIONOMICS LIMITED
    Inventor: Jose Iglesias
  • Patent number: 10137105
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 27, 2018
    Assignee: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • Publication number: 20180196048
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE
  • Publication number: 20180196056
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE
  • Publication number: 20180161302
    Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 14, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
  • Patent number: 9987293
    Abstract: The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC 105P.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 5, 2018
    Assignee: BIONOMICS LIMITED
    Inventors: Alan R. Eastman, Darcy Bates
  • Patent number: 9975892
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 22, 2018
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Publication number: 20180105523
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Publication number: 20180105524
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Patent number: 9914702
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 13, 2018
    Assignees: Bionomics Limited, Merck Patent GmbH
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Publication number: 20180042887
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Application
    Filed: March 2, 2016
    Publication date: February 15, 2018
    Applicant: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • Patent number: 9758516
    Abstract: A crystalline Form B of compound 1 can be used in pharmaceutically compositions. The pharmaceutical compositions can be used in methods of treating a disease (e.g., a disease of the central nervous system).
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: September 12, 2017
    Assignee: BIONOMICS LIMITED
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey
  • Patent number: 9745296
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Publication number: 20170183347
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: January 4, 2017
    Publication date: June 29, 2017
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Publication number: 20170135980
    Abstract: The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
    Type: Application
    Filed: March 18, 2015
    Publication date: May 18, 2017
    Applicant: BIONOMICS LIMITED
    Inventor: Jose IGLESIAS
  • Publication number: 20170119727
    Abstract: The present invention is directed to a pharmaceutical combination for treating proliferative disease comprising a compound of formula (I), or a salt, solvate or prodrug thereof, carboplatin or cisplatin, and gemcitabine. The present invention is further directed to a therapeutic protocol to manage ovarian cancer treatment in a female subject involving the administration of the combination to an ovarian cancer subject with recurrent or persistent ovarian cancer following treatment with platinum-based therapy. Kits comprising the combination as well as the use of the combination in the treatment of a proliferative disease are further contemplated.
    Type: Application
    Filed: May 30, 2014
    Publication date: May 4, 2017
    Applicant: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, David C. BIBBY, Danny RISCHIN
  • Patent number: 9573945
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: February 21, 2017
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui